Ligand Pharmaceuticals LGND EBIT

EBIT at other companies

Royalty PharmaRPRX

$133.12M-36.5%

Relay Therapeutics, Inc.RLAY

-$90.82M-18.2%

Ionis PharmaceuticalsIONS

-$102.29M-173%

Innoviva, Inc.INVA

$50.86M+4.3%

Rigel PharmaceuticalsRIGL

$11.89M-7.0%

Opko HealthOPK

-$6.97M+88.4%

FAQ

What is Ligand Pharmaceuticals's EBIT?

Ligand Pharmaceuticals (LGND) reported EBIT of $8.59M in Q2 2026.

How has Ligand Pharmaceuticals's EBIT changed year-over-year?

Ligand Pharmaceuticals's EBIT increased by 1.7% year-over-year, from $8.44M to $8.59M.

What is the long-term trend for Ligand Pharmaceuticals's EBIT?

Over 4 years (2021 to 2025), Ligand Pharmaceuticals's EBIT has grown at a -20.7% compound annual growth rate (CAGR), from $103.85M to $41M.

What does EBIT mean?

Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.